Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $52.00 at Mizuho

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price cut by Mizuho from $60.00 to $52.00 in a report published on Monday morning, Benzinga reports. They currently have a neutral rating on the stock.

APLS has been the subject of a number of other research reports. The Goldman Sachs Group increased their price target on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a buy rating in a research note on Tuesday, January 9th. Raymond James increased their price target on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a strong-buy rating in a research note on Thursday, January 11th. Robert W. Baird restated an outperform rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Finally, Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a hold rating to a buy rating and raised their target price for the stock from $68.00 to $80.00 in a research note on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $77.40.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $47.84 on Monday. The stock has a market capitalization of $5.77 billion, a PE ratio of -10.68 and a beta of 0.88. Apellis Pharmaceuticals has a 1-year low of $19.83 and a 1-year high of $94.75. The firm has a fifty day simple moving average of $57.42 and a 200 day simple moving average of $57.56. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.50) earnings per share. On average, research analysts expect that Apellis Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Adam J. Townsend sold 1,148 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $77,799.96. Following the completion of the transaction, the insider now directly owns 92,453 shares in the company, valued at $6,265,539.81. The disclosure for this sale can be found here. Over the last three months, insiders have sold 376,427 shares of company stock valued at $23,169,639. 7.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. grew its holdings in shares of Apellis Pharmaceuticals by 254.5% during the 1st quarter. Principal Financial Group Inc. now owns 84,604 shares of the company’s stock valued at $4,973,000 after purchasing an additional 60,741 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Apellis Pharmaceuticals by 69.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 23,182 shares of the company’s stock valued at $1,363,000 after purchasing an additional 9,472 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at approximately $5,447,000. Simplicity Wealth LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at approximately $4,599,000. Finally, Summit Trail Advisors LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at approximately $262,000. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).